Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cytek BiosciencesCTKB +1.07%71 Intrinsic Value: Projected FCF is $1.97 as of Aug. 21, 2026, which is 12% below its 10-year median of 2.25. GuruFocus rates CTKB with a GF Score™ of 71/100 and a GF Value™ of $5.52 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 406 Medical Devices & Instruments companies, Cytek Biosciences ranks worse than 68.97% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
As of today (2026-08-21), Cytek Biosciences's Intrinsic Value: Projected FCF is $1.97. The stock price of Cytek Biosciences is $4.71. Therefore, Cytek Biosciences's Price-to-Intrinsic-Value-Projected-FCF of today is 2.4.
The historical rank and industry rank for Cytek Biosciences's Intrinsic Value: Projected FCF or its related term are showing as below:
CTKB'
s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 2.14 Med: 2.25 Max: 2.41
Current: 2.39
During the past 7 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Cytek Biosciences was 2.41. The lowest was 2.14. And the median was 2.25.
CTKB's Price-to-Projected-FCF is ranked worse than 68.97% of 406
companies
in the Medical Devices & Instruments industry
Industry Median: 1.5
vs CTKB: 2.39
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Cytek Biosciences's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
4.71
/
1.9670661459516
=
2.39
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cytek Biosciences Intrinsic Value: Projected FCF Related Terms
Cytek Biosciences Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Cytek Biosciences's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTKB vs CERS, TCMD, CBLL: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Cytek Biosciences's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cytek Biosciences Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cytek Biosciences's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Cytek Biosciences's Price-to-Projected-FCF falls into.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of $1.97 mean?
Cytek Biosciences (CTKB) has a Intrinsic Value: Projected FCF of $1.97 as of Aug. 21, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Cytek Biosciences and its competitors. This is 12% below median its historical median of 2.25. Over the past decade, Cytek Biosciences' Intrinsic Value: Projected FCF has ranged from 2.14 to 2.41. According to the industry distribution chart, Cytek Biosciences ranks #280 out of 406 companies in the Medical Devices & Instruments industry, placing it in the top 69%.
Is Cytek Biosciences' Intrinsic Value: Projected FCF too high?
Cytek Biosciences' current Intrinsic Value: Projected FCF of $1.97 is 12% below median its 10-year median of 2.25. Over the past 10 years, this metric has ranged from a low of 2.14 to a high of 2.41. The Medical Devices & Instruments industry median Intrinsic Value: Projected FCF is 1.50. Cytek Biosciences' value of $1.97 is 31.3% above this industry median. Based on the distribution chart, Cytek Biosciences ranks #280 out of 406 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Cytek Biosciences has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cytek Biosciences' Intrinsic Value: Projected FCF compare to CERS and TCMD?
According to the Medical Devices & Instruments industry distribution chart, Cytek Biosciences ranks #280 out of 406 companies for Intrinsic Value: Projected FCF. This places Cytek Biosciences in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.50. Cytek Biosciences' value of $1.97 is 31.3% above this benchmark. Historically, Cytek Biosciences' own Intrinsic Value: Projected FCF has ranged from 2.14 to 2.41 over the past decade. While the company's 10-year median is 2.25 vs. the industry median of 1.50, Cytek Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.50, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cytek Biosciences's current Intrinsic Value: Projected FCF of $1.97 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Cytek Biosciences and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cytek Biosciences's current Intrinsic Value: Projected FCF is $1.97, which is 12% below median its own 10-year median of 2.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytek Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Cytek Biosciences (CTKB) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.52, compared to a current price of $4.71 — trading 14.7% below its estimated fair value. The current Intrinsic Value: Projected FCF is $1.97, which is 12% below median its 10-year median of 2.25 and 31.3% above the Medical Devices & Instruments industry median of 1.50. Cytek Biosciences' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Cytek Biosciences (CTKB), the current Intrinsic Value: Projected FCF is $1.97 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cytek Biosciences (CTKB) Overvalued in 2026?
Based on GuruFocus' analysis, Cytek Biosciences stock appears to be undervalued.
The current stock price of $4.71 is trading 14.7% below its estimated GF Value™ of $5.52.
GuruFocus considers Cytek Biosciences to be Modestly Undervalued.
Key valuation signals for CTKB:
Intrinsic Value: Projected FCF: $1.97 (12% below median its 10-year median of 2.25)
GF Value™: $5.52 vs. price of $4.71 (14.7% below fair value)
Industry Position: 31.3% above the Medical Devices & Instruments median (#280 of 406)
No single metric tells the full story. See the CTKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
71GF Score
Get the complete analysis for CTKB
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTKB has been successfully added to your 
